Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Intangibles (2019 - 2025)

BridgeBio Pharma's Intangibles history spans 5 years, with the latest figure at $23.9 million for Q4 2024.

  • For Q4 2024, Intangibles fell 9.09% year-over-year to $23.9 million; the TTM value through Dec 2024 reached $23.9 million, down 9.09%, while the annual FY2024 figure was $23.9 million, 9.09% down from the prior year.
  • Intangibles for Q4 2024 was $23.9 million at BridgeBio Pharma, down from $26.3 million in the prior quarter.
  • Across five years, Intangibles topped out at $30.5 million in Q1 2022 and bottomed at $15.0 million in Q4 2021.
  • The 4-year median for Intangibles is $28.4 million (2022), against an average of $26.5 million.
  • The largest annual shift saw Intangibles surged 91.41% in 2022 before it fell 9.09% in 2024.
  • A 4-year view of Intangibles shows it stood at $15.0 million in 2021, then soared by 91.41% to $28.7 million in 2022, then dropped by 8.33% to $26.3 million in 2023, then decreased by 9.09% to $23.9 million in 2024.
  • Per Business Quant, the three most recent readings for BBIO's Intangibles are $23.9 million (Q4 2024), $26.3 million (Q4 2023), and $28.1 million (Q1 2023).